ResMed (ASX:RMD) is still batting eyelashes at brokers, with Ord Minnett reaffirming its “Buy” rating following what it called a “solid” quarterly performance. Listen to the HotCopper podcast for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback